Thanks Mr. North,
Is this an improved opinion?
---
🏛️ Mock Supreme Court Opinion (Reversal & Remand)
Justice Barrett delivered the opinion of the Court.
This case concerns the standard for evaluating a claim of induced infringement at the pleading stage when a generic drug manufacturer has obtained FDA approval for a “skinny label” that omits a patented indication. The District Court dismissed Amarin’s complaint at the outset, concluding that Hikma’s label and marketing could not, as a matter of law, plausibly encourage physicians to prescribe the drug for the patented cardiovascular-risk-reduction use. The Court of Appeals reversed. We affirm the judgment of the Court of Appeals and remand for further proceedings.
---
I
Under Rule 12(b)(6), a court must accept the complaint’s factual allegations as true and determine whether they state a claim that is plausible on its face. Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). That standard does not permit a court to weigh competing inferences, resolve factual disputes, or demand evidentiary proof. The question is simply whether the complaint alleges conduct that, if proven, could constitute induced infringement under 35 U.S.C. §271(b).
The District Court departed from that framework. Rather than assume the truth of Amarin’s allegations, it evaluated Hikma’s intent, parsed the meaning of its marketing statements, and treated the FDA’s approval of a carved-out label as dispositive. That approach conflated the pleading stage with summary judgment.
---
II
Amarin alleges that Hikma, while omitting the patented cardiovascular indication from its label, nonetheless promoted its product in a manner that encouraged physicians to prescribe it for that very use. The complaint points to Hikma’s repeated references to its product as “generic Vascepa,” its invocation of clinical data associated with the patented indication, and its use of terminology broader than the carved-in severe-hypertriglyceridemia indication.
At this stage, we do not decide whether those allegations are true or whether Hikma in fact induced infringement. We decide only whether the allegations, taken as true, plausibly describe conduct that could amount to inducement. They do.
A manufacturer may not evade §271(b) simply by carving out a patented indication if its marketing or labeling nonetheless encourages the patented use. The statute contains no safe harbor insulating a generic manufacturer from inducement liability solely because it has obtained FDA approval for a skinny label. Nor do we adopt the categorical rule Hikma proposes, which would render inducement claims effectively impossible to plead in this context.
---
III
Hikma argues that its compliance with FDA labeling requirements forecloses liability. But FDA approval does not immunize conduct that otherwise satisfies the elements of inducement. The FDA’s regulatory determinations do not displace the Patent Act, and nothing in the statute suggests that a carve-out label precludes liability where the manufacturer’s own statements plausibly encourage the patented use.
The District Court’s contrary reasoning rested on a misunderstanding of both the regulatory framework and the pleading standard. Whether Hikma’s statements in fact induced infringement is a factual question for later stages of litigation.
---
IV
We express no view on the ultimate merits. The only question before us is whether Amarin’s complaint states a plausible claim. Because the District Court applied an unduly restrictive standard and resolved factual disputes inappropriate for a motion to dismiss, its judgment cannot stand.
The judgment of the Court of Appeals is affirmed, and the case is remanded for further proceedings consistent with this opinion.
It is so ordered.
Market Data 
Markets 
AI
